Population Immunity of Natural Infection, Primary-series Vaccination, and Booster Vaccination in Qatar During the COVID-19 Pandemic: an Observational Study

Background: Waning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination are defined, respectively, as the overall protection against reinfection or against breakthrough infection at a given point in time in a given population.

Methods: We estimated these population immunities in Qatar's population between July 1, 2020 and November 30, 2022, to discern generic features of the epidemiology of SARS-CoV-2. Effectiveness of previous infection, mRNA primary-series vaccination, and mRNA booster (third-dose) vaccination in preventing infection were estimated, month by month, using matched, test-negative, case-control studies.

Findings: Previous-infection effectiveness against reinfection was strong before emergence of Omicron, but declined with time after a wave and rebounded after a new wave. Effectiveness dropped after Omicron emergence from 88.3% (95% CI: 84.8-91.0%) in November 2021 to 51.0% (95% CI: 48.3-53.6%) in December 2021. Primary-series effectiveness against infection was 84.0% (95% CI: 83.0-85.0%) in April 2021, soon after introduction of vaccination, before waning gradually to 52.7% (95% CI: 46.5-58.2%) by November 2021. Effectiveness declined linearly by ∼1 percentage point every 5 days. After Omicron emergence, effectiveness dropped from 52.7% (95% CI: 46.5-58.2%) in November 2021 to negligible levels in December 2021. Booster effectiveness dropped after Omicron emergence from 83.0% (95% CI: 65.6-91.6%) in November 2021 to 32.9% (95% CI: 26.7-38.5%) in December 2021, and continued to decline thereafter. Effectiveness of previous infection and vaccination against severe, critical, or fatal COVID-19 were generally >80% throughout the study duration.

Interpretation: High population immunity against infection may not be sustained beyond a year, but population immunity against severe COVID-19 is durable with slow waning even after Omicron emergence.

Funding: The Biomedical Research Program and the Biostatistics, Epidemiology, and the Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, Qatar University Biomedical Research Center, and Qatar University Internal Grant ID QUCG-CAS-23/24-114.

Citing Articles

All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data.

Alessandria M, Malatesta G, Di Palmo G, Cosentino M, Donzelli A F1000Res. 2025; 13:886.

PMID: 40028449 PMC: 11868741. DOI: 10.12688/f1000research.154058.2.

Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar.

Chemaitelly H, Ayoub H, Faust J, Coyle P, Tang P, Hasan M BMJ Public Health. 2025; 1(1):e000479.

PMID: 40017867 PMC: 11812731. DOI: 10.1136/bmjph-2023-000479.

EMSIG: Uncovering Factors Influencing COVID-19 Vaccination Across Different Subgroups Characterized by Embedding-Based Spatial Information Gain.

Yue Z, McCormick N, Ezeala O, Durham S, Westrick S Vaccines (Basel). 2024; 12(11).

PMID: 39591156 PMC: 11599077. DOI: 10.3390/vaccines12111253.

Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.

Jongkees M, Tan N, Geers D, de Vries R, GeurtsvanKessel C, Hensley K AIDS. 2024; 38(9):1355-1365.

PMID: 38788210 PMC: 11216395. DOI: 10.1097/QAD.0000000000003933.

SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study.

Mahmoud M, Ayoub H, Coyle P, Tang P, Hasan M, Yassine H Influenza Other Respir Viruses. 2023; 17(11):e13224.

PMID: 38019700 PMC: 10663173. DOI: 10.1111/irv.13224.

References

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

Abu-Raddad L, Chemaitelly H, Ayoub H, Coyle P, Malek J, Ahmed A . Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med. 2021; 18(12):e1003879. PMC: 8726501. DOI: 10.1371/journal.pmed.1003879. View

Jackson M, Nelson J . The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013; 31(17):2165-8. DOI: 10.1016/j.vaccine.2013.02.053. View

Jeremijenko A, Chemaitelly H, Ayoub H, Alishaq M, Abou-Samra A, Al Ajmi J . Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis. 2021; 27(5):1343-1352. PMC: 8084480. DOI: 10.3201/eid2705.204365. View

Chemaitelly H, Ayoub H, Almukdad S, Faust J, Tang P, Coyle P . Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections. J Travel Med. 2023; 30(5). PMC: 10481416. DOI: 10.1093/jtm/taad106. View

Abu-Raddad L, Chemaitelly H, Ayoub H, Almukdad S, Yassine H, Al-Khatib H . Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med. 2022; 386(19):1804-1816. PMC: 8929389. DOI: 10.1056/NEJMoa2200797. View

Abu-Raddad L, Chemaitelly H, Malek J, Ahmed A, Mohamoud Y, Younuskunju S . Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clin Infect Dis. 2020; 73(7):e1830-e1840. PMC: 7799253. DOI: 10.1093/cid/ciaa1846. View

Janjua N, Skowronski D, Hottes T, Osei W, Adams E, Petric M . Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis. 2010; 51(9):1017-27. PMC: 7107856. DOI: 10.1086/656586. View

Tang P, Hasan M, Chemaitelly H, Yassine H, Benslimane F, Al Khatib H . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021; 27(12):2136-2143. DOI: 10.1038/s41591-021-01583-4. View

10.

Ayoub H, Tomy M, Chemaitelly H, Altarawneh H, Coyle P, Tang P . Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design. Am J Epidemiol. 2023; 193(6):883-897. PMC: 11145912. DOI: 10.1093/aje/kwad239. View

11.

Chemaitelly H, Faust J, Krumholz H, Ayoub H, Tang P, Coyle P . Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. Int J Infect Dis. 2023; 136:81-90. DOI: 10.1016/j.ijid.2023.09.005. View

12.

Verani J, Baqui A, Broome C, Cherian T, Cohen C, Farrar J . Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017; 35(25):3295-3302. PMC: 7007298. DOI: 10.1016/j.vaccine.2017.04.037. View

13.

Higdon M, Wahl B, Jones C, Rosen J, Truelove S, Baidya A . A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infect Dis. 2022; 9(6):ofac138. PMC: 9047227. DOI: 10.1093/ofid/ofac138. View

14.

Subissi L, von Gottberg A, Thukral L, Worp N, Oude Munnink B, Rathore S . An early warning system for emerging SARS-CoV-2 variants. Nat Med. 2022; 28(6):1110-1115. PMC: 11346314. DOI: 10.1038/s41591-022-01836-w. View

15.

Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View

16.

Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis J . SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022; 209:112911. PMC: 8824301. DOI: 10.1016/j.envres.2022.112911. View

17.

Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

18.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

19.

Altarawneh H, Chemaitelly H, Ayoub H, Hasan M, Coyle P, Yassine H . Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med. 2022; 387(17):1620-1622. PMC: 9559315. DOI: 10.1056/NEJMc2209306. View

20.

Skowronski D, Sabaiduc S, Leir S, Rose C, Zou M, Murti M . Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Euro Surveill. 2019; 24(46). PMC: 6864978. DOI: 10.2807/1560-7917.ES.2019.24.46.1900585. View